Australia markets closed
  • ALL ORDS

    7,358.70
    +1.00 (+0.01%)
     
  • ASX 200

    7,114.50
    +1.70 (+0.02%)
     
  • AUD/USD

    0.6876
    -0.0039 (-0.57%)
     
  • OIL

    90.09
    -0.41 (-0.45%)
     
  • GOLD

    1,761.70
    -9.50 (-0.54%)
     
  • BTC-AUD

    31,087.43
    -3,016.38 (-8.84%)
     
  • CMC Crypto 200

    507.80
    -33.80 (-6.24%)
     
  • AUD/EUR

    0.6844
    -0.0002 (-0.02%)
     
  • AUD/NZD

    1.1128
    +0.0085 (+0.77%)
     
  • NZX 50

    11,684.81
    -129.53 (-1.10%)
     
  • NASDAQ

    13,236.80
    -269.19 (-1.99%)
     
  • FTSE

    7,550.37
    +8.52 (+0.11%)
     
  • Dow Jones

    33,716.88
    -282.16 (-0.83%)
     
  • DAX

    13,544.52
    -152.89 (-1.12%)
     
  • Hang Seng

    19,773.03
    +9.12 (+0.05%)
     
  • NIKKEI 225

    28,930.33
    -11.77 (-0.04%)
     

Calroy Health Sciences Establishes Science and Medical Advisory Board

·8-min read

Clinical, science, and natural products industry experts to advance Company’s research, clinical studies, and product development strategies

SCOTTSDALE, Ariz., December 02, 2021--(BUSINESS WIRE)--Calroy Health Sciences, a company dedicated to developing innovative natural solutions to optimize cardiovascular health, today announced the establishment of a science and medical advisory board comprised of leading researchers and clinicians representing diverse specialties in science and medicine and the natural products industry. The newly appointed board will provide strategic input, recommendations, and critical evaluation needed to advance Calroy’s education, research, and product development. Calroy is making significant investment in research to further demonstrate the clinical efficacy and effectiveness of its cardiovascular support product, Arterosil®, the only dietary supplement with a U.S. patent targeting vulnerable plaque.

"Our new science and medical advisory board represents a distinguished group of individuals who are well-respected educators, clinicians, and researchers," said Ed Hoyt, president and chief executive officer of Calroy Health Sciences. "Calroy will draw on the board’s expansive knowledge to evaluate, advise, and integrate emerging scientific and clinical developments, technologies, and innovations throughout Calroy’s core business and strategic plan."

"Collaboration with distinguished scientists, researchers, and clinicians has been invaluable to Calroy in bringing Arterosil, the trailblazer for endothelial glycocalyx restoration, to people interested in optimizing their vascular health," said Chen Chen, Ph.D., chief scientific officer of Calroy Health Sciences and science and medical advisory board chair. "The new board will guide us through the rapidly advancing biomedical science and technology landscape. I am excited to work with the board to fulfill our commitment to drive new science-based solutions to major health challenges."

Inaugural members of the science and medical advisory board include the following global experts:

Victor Atallah, M.D.

Dr. Atallah, honorary consul of The State of Palestine in Dominican Republic, is founder and director of the first nuclear medicine program, the Department of Nuclear Cardiology, at the Center for Diagnosis, Advanced Medicine and Telemedicine, Corazones Unidos. He also serves as a professor of cardiology at Hospital Dr. Salvador Bienvenido Gautier and Instituto Dominicano de Cardiología (IDC), El Instituto Tecnológico de Santo Domingo (INTEC) and Universidad Iberoamericana. Dr. Atallah received his M.D. from INTEC and postgraduate degrees in cardiology, nuclear cardiology and interventional cardiology from Lenox Hill Hospital in New York, NY. He earned a diploma from the American Board of Internal Medicine and Nuclear Cardiology and is board certified by the American College of Cardiology.

Kristine Burke, M.D.

Dr. Burke, medical director and CEO of the True Health Center for Functional Medicine in El Dorado Hills, CA, specializes in family, sports, and functional medicine. She also has served as chief of family medicine at Mercy Hospital of Folsom, assistant clinical professor of preventive medicine at Loma Linda School of Medicine, and as an educator and facilitator for the Institute for Functional Medicine. Additionally, she contributed to the development of the COVID-19 Virtual Care pathway for VirtualPractices.org and The Institute for Functional Medicine’s COVID-19 Task Force. Dr. Burke received her M.D. at University of California School of Medicine in Davis, Calif., and is board certified in family medicine, sports medicine, and integrative medicine.

Chen Chen, Ph.D.

Dr. Chen is co-founder and chief scientific officer, Calroy Health Sciences, and Calroy’s science and medical advisory board chair. He has founded and helped to grow numerous business ventures, successfully bringing innovative health ingredients, novel nutritional supplements, and unique medical devices to the global market. In addition to championing healthy lipids, Dr. Chen has conducted extensive studies on functional carbohydrates and participates in the R&D of some of the most innovative products on the market, such as Arterosil®. He is directing a state-of-the-art research program on glyco-bioengineering and glyco-therapeutics at Calroy. He holds a graduate degree in Business Management and earned M.S. and Ph.D. degrees in Nutritional Science.

Chris D’Adamo, Ph.D.

Dr. Chris D’Adamo, director of the center for integrative medicine at the University of Maryland School of Medicine, is a medical research scientist with expertise in the synergistic effects of healthy lifestyle, environmental exposures, and genetics on human health and wellness. His research, clinical, and educational network includes leaders in the fields of integrative medicine, functional medicine, and lifestyle medicine. He has served as principal investigator on a variety of clinical trials and observational studies in the areas of nutrition, physical activity, stress management, and multi-modality integrative and functional medicine interventions, and contributed to over 50 publications in peer-reviewed scientific and medical journals. He also contributed to medical textbooks and lectures worldwide about nutrition, physical activity, stress management, and other topics in integrative, functional, and lifestyle medicine. Dr. D’Adamo earned his Ph.D. in epidemiology at University of Maryland School of Medicine in Baltimore, Md.

Mark Failla, Ph.D.

A professor emeritus at Ohio State University and an elected fellow of the American Association for the Advancement of Science, Dr. Failla specializes in health nutrition focusing on digestion, absorption, intestinal metabolism, bioactive compounds, gut health, and bioavailability. He received his Ph.D. in microbiology at Indiana University in Bloomington, Ind., and completed post-doctoral research in nutritional biochemistry at Rutgers University in New Brunswick, N.J.

Laurie Hofmann, M.P.H.

Ms. Hofmann, partner at Ovation Lab and co-founder of VirtualPractices, is a seasoned executive, board chair and strategic advisor who has executed global development initiatives for leading functional medicine professional education and training organizations, health care systems and industry leaders. Ms. Hofmann's 30-year track record of accomplishments in health and wellness, functional medicine, public health, personalized nutrition, science-based natural medicine, process and strategic planning, and complex dialogue facilitation has served to advance and expand awareness, reach, and traction of functional medicine and personalized nutrition. She earned her M.P.H. at University of New Mexico School of Medicine.

Mark Houston, M.D.

Dr. Houston is founder of the Hypertension Institute in Nashville, Tenn., currently serving as director of vascular biology and medical director of clinical research and human nutrition. He specializes in hypertension, lipid disorders, prevention and treatment of cardiovascular diseases, nutrition, clinical age management, and general internal medicine and is boarded in hypertension as an American Society of Hypertension specialist and fellow of the American Society of Hypertension, Internal Medicine and Anti-aging Medicine. He is also the director and faculty for the Advanced Cardiovascular Modules and fellowship program for A4M/MMI. Additionally, he has published nine books and served as the editor for Personalized and Precision Integrative Cardiovascular Medicine. Dr. Houston received his M.D. at Vanderbilt University School of Medicine in Nashville, TN.

Loren Israelsen, J.D.

Mr. Israelsen, founder and president of the United Natural Products Alliance (UNPA), an international trade association of dietary supplement companies committed to safety, science and quality, has over 40 years of experience navigating the commercial and regulatory issues facing the global dietary supplement industry. He has served as general counsel and president of Nature’s Way Products, Inc., vice president and general counsel to the American Herbal Products Association, co-founder and counsel to the European American Phytomedicine Coalition (EAPC) and is a founding member of the International Alliance of Dietary/Food Supplement Associations (IADSA). Mr. Israelsen earned his J.D. in law at Brigham Young University in Provo, UT.

Helen Messier, M.D., Ph.D

Focused on data-driven healthcare models, Dr. Messier founded a series of national concierge practices, including Medical Intelligence Learning Labs Inc, and is a family medicine doctor at Altum Medical. Her real-time translation of precision medicine integrates multi-omics technologies and applies them directly in clinical care, allowing patients with complex chronic disease to actively benefit from innovative biomedical technologies. Previously, she served as medical director of genomics at the Human Longevity Institute and chief medical officer of Viome. Dr. Messier earned her Ph.D. in molecular immunology at University of Alberta in Edmonton, Alberta, and received her M.D. from University of Calgary in Calgary, Alberta.

Bob Sheeler, M.D.

Dr. Sheeler is an experienced physician with a demonstrated history of working in the health and science field and extensive knowledge in clinical care, clinical research, medical and scientific writing, and medical education. For over 20 years, he practiced as a physician and held leadership positions at Mayo Clinic. There he also served as clinical practice chair and as an associate professor for the department of family medicine, as well as medical editor for Mayo Clinic Health Letter+. Additionally, he is board certified in headache medicine, family medicine, integrative medicine, holistic medicine, and urgent care and earned certification in functional medicine from the Institute of Functional Medicine. Dr. Sheeler received his M.D., from the University of California School of Medicine in San Diego, CA.

For more information about Calroy Health Sciences, visit https://calroy.com. To learn more about Arterosil®, go to https://arterosil.com.

About Calroy Health Sciences

Calroy Health Sciences is a company dedicated to science-based innovations that transform human health with natural solutions. Its mission is to develop innovative therapies aimed at optimizing cardiovascular health. Calroy invests heavily in research and clinical studies to support its specific formulations as part of its approach and commitment to customers. Arterosil® is a unique product offered by Calroy to protect and restore the endothelial glycocalyx, the microscopic gel-like lining that naturally protects the endothelium.

About Arterosil®

Arterosil® is a dietary supplement clinically proven to protect and restore the endothelial glycocalyx, the slippery lining that helps regulate the access of potentially plaque-causing cholesterol to the vascular endothelium. Arterosil contains MonitumRS™ - a proprietary extract of rhamnan sulfate, a specialized sulfated polysaccharide derived from the rare green seaweed, Monostroma nitidum. Rhamnan sulfate is a powerful glycocalyx-regenerating compound and has been reported to possess many cardiovascular health benefits. Arterosil® is manufactured in the U.S.A. and available through licensed healthcare professionals.

The method by which Arterosil helps to stabilize and regress vulnerable plaque is covered under U.S. Patent 11,135,238.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211202005176/en/

Contacts

Media:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
+1.973.818.8198

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting